Earning Analysis
Welcome to our in-depth analysis of DarioHealth Corp(DRIO) earnings, offering investors a detailed look into the company’s financial performance, revenue trends, earnings per share (EPS), and market reactions. This page provides a comprehensive overview of DarioHealth Corp earnings history, forecasts, and key financial metrics, empowering you with the data needed to make informed investment decisions. Whether you're tracking quarterly results, analyzing earnings surprises, or exploring future projections, our detailed breakdown covers it all.
Earnings Forecast
Revenue
EPS
Currency: USD
Actual
Estimate
Surprise Analysis
| FY2025Q3 | 2025-11-13 | Pre-Market | -2.63 | -1.63 | +38.02 | 5.67M | 5.01M | -11.62 | -15.57 | +12.51 |
| FY2025Q2 | 2025-08-12 | Pre-Market | -0.20 | -0.18 | +10.00 | 6.91M | 5.37M | -22.24 | -14.85 | -10.93 |
| FY2025Q1 | 2025-05-14 | Pre-Market | -0.12 | -0.14 | -16.67 | 7.47M | 6.75M | -9.67 | -8.50 | -8.50 |
| FY2024Q4 | 2025-03-10 | Pre-Market | -0.31 | -0.09 | +70.97 | 7.39M | 7.60M | +2.95 | -7.96 | -8.67 |
| FY2024Q2 | 2024-08-08 | Pre-Market | -0.51 | -0.08 | -84.31 | 7.92M | 6.26M | -20.98 | -9.92 | -1.29 |
| - | 2024-05-15 | - | -0.59 | -0.20 | +66.10 | - | - | - | +6.94 | +4.62 |
| FY2023Q4 | 2024-03-28 | - | -0.54 | -0.41 | +24.07 | 3.78M | 3.62M | -4.22 | +0.66 | -9.21 |
| FY2023Q3 | 2023-11-02 | - | -0.50 | -0.49 | +2.00 | 5.42M | 3.52M | -35.10 | - | +18.81 |
| FY2023Q2 | 2023-08-10 | - | -0.52 | -0.58 | -11.54 | 6.01M | 6.15M | +2.33 | -8.43 | -22.97 |
| - | 2023-05-11 | - | -0.46 | 0.45 | +197.83 | - | - | - | +4.32 | +0.54 |
DRIO Earnings Analysis
Our earnings analysis provides a granular look at the company’s performance across recent fiscal quarters, highlighting key metrics such as revenue, EPS, and operating margins. By examining actual results against analyst estimates, we uncover trends and surprises that drive stock price movements, offering valuable insights for both short-term traders and long-term investors.
In the most recent quarter, DarioHealth Corp reported performance for FY2025Q3, announced on 2025-11-13. The company achieved an EPS of -1.63, compared to analyst estimates of -2.63 by 38.02% . Revenue for the quarter reached 5.01M compared to expectations of 5.67M by -11.62% .
The stock price reacted with a -15.57% one-day change and a 12.51% five-day change following the earnings release. These movements reflect market reaction in DarioHealth Corp growth trajectory and strategic initiatives.
DRIO Earnings Forecast
Looking ahead, DarioHealth Corp(DRIO) remains a focal point for investors seeking growth opportunities. Analyst forecasts for 2025/Q4 project quarter revenue of 5.10M and an EPS of -5.34.
However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for FY2025 have been Revise Downward by -6.84%, while EPS estimates have been Revise Downward by -17.85%. For the upcoming Q4 2025, revenue estimates have been adjusted Revise Downward by -15.92% . These revisions correlate with a 25.52% change in stock price over the same period, suggesting potential buying opportunities for investors who believe in DarioHealth Corp long-term fundamentals.
The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.
Estimate Revision
The chart shows the correlation between DRIO's stock price and earnings forecast revisions. Positive revisions in Revenue or EPS often strengthen the stock's fundamentals, making price dips potential buying opportunities.
Revenue Estimates for FY2025
Revise Downward
-6.84%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
-17.85%
In Past 3 Month
Revenue Estimates for Q4 2025
Revise Downward
-15.92%
In Past 3 Month
Stock Price
Go Up
+25.52%
In Past 3 Month
1Y
3Y
5Y
Annual FY 2025
Currency: USD
1Y
3Y
5Y
--
Revenue Estimate-Annual FY 2025:22.29M
--
EPS Estimate-Annual FY 2025:-13.78
—
Stock Price12.05
DRIO Revenue and EPS Performance: A Historical Perspective
DarioHealth Corp revenue and earnings per share (EPS) performance over recent quarters provides a clear picture of its financial health. Below is a detailed breakdown of the company’s earnings history, showcasing actual results, analyst estimates, and surprise percentages for key fiscal quarters:
FY2025Q3 (2025-11-13,Pre-Market):
EPS: -1.63 (Actual) vs.-2.63 (Estimate) (38.02%)
Revenue: 5.01M (Actual) vs. 5.67M (Estimate) (-11.62%)
Price Reaction: -15.57%(1-Day), 12.51%(5-Day)
FY2025Q2 (2025-08-12,Pre-Market):
EPS: -0.18 (Actual) vs.-0.20 (Estimate) (10.00%)
Revenue: 5.37M (Actual) vs. 6.91M (Estimate) (-22.24%)
Price Reaction: -14.85%(1-Day), -10.93%(5-Day)
FY2025Q1 (2025-05-14,Pre-Market):
EPS: -0.14 (Actual) vs.-0.12 (Estimate) (-16.67%)
Revenue: 6.75M (Actual) vs. 7.47M (Estimate) (-9.67%)
Price Reaction: -8.50%(1-Day), -8.50%(5-Day)
Earnings Reaction
The chart below shows how DRIO performed 10 days before and after its earnings report, based on data from the past quarters. Typically, DRIO sees a +26.14% change in stock price 10 days leading up to the earnings, and a +0.98% change 10 days following the report. On the earnings day itself, the stock moves by -5.33%. This data can give you a slight idea of what to expect for the next quarter's release.
For example, in SEP/2025, the stock changed 18.25% on the day following the earnings release and then changed by 20.36% over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.
Transcript Summary
DarioHealth Corp (DRIO) Q3 2025 Earnings Call Summary
Neutral
2025-11-13
The earnings call summary presents a mixed picture. Financial performance shows improvement in gross margins and operating losses, but revenue declined, raising concerns. Product development and market strategy are positive, with new partnerships and client growth. However, cash flow breakeven delay and lack of specific guidance in Q&A dampen optimism. Shareholder returns weren't discussed. Overall, the sentiment is neutral, reflecting balanced positive and negative factors.
DarioHealth Corp (DRIO) Q2 2025 Earnings Call Summary
Negative
2025-08-12
The earnings call reveals several concerning factors: a 14.3% revenue decline, delayed cash flow breakeven, and client onboarding issues. Despite cost reductions and improved gross margins, the strategic shift to a SaaS model and competitive pressures pose risks. Q&A highlights management's unclear responses on financial impacts, further contributing to uncertainty. These factors suggest a negative sentiment, likely impacting the stock price negatively in the short term.
DarioHealth Corp (DRIO) Q1 2025 Earnings Call Summary
Neutral
2025-05-15
The earnings call presented a mixed picture. Financial performance showed improvement in revenue and reduced operating expenses, but the EPS miss and tariff-related delays are concerning. The Q&A highlighted uncertainties, especially regarding pharma contracts and health plan transitions. Positive aspects include new partnerships and client growth, but the lack of a share buyback program and competitive pressures are negatives. Overall, the sentiment is neutral, as positive developments are balanced by risks and uncertainties.
DarioHealth Corp (DRIO) Q1 2025 Earnings Call Summary
Positive
2025-05-14
The earnings call highlights strong financial performance with a 17% revenue increase and improved margins. The acquisition of Twill and new pharma partnerships, along with a focus on cash flow breakeven, are positive indicators. Despite some tariff-related delays, the overall sentiment is positive with high client renewal rates and strategic growth plans. The market cap is unavailable, but the company's strategic initiatives and financial health suggest a likely positive stock price movement in the short term.
DarioHealth Corp (DRIO) Q4 2024 Earnings Call Summary
Positive
2025-03-11
The earnings call indicates strong financial performance with significant revenue growth and improved margins. The partnership with AARP and a transition to a subscription model are positive strategic moves. While there are some uncertainties in guidance and operational risks, the overall sentiment is positive, with a focus on profitability and expansion. The Q&A section adds confidence in growth prospects, despite some unclear responses. The positive elements outweigh the risks, suggesting a likely stock price increase in the short term.
DarioHealth Corp (DRIO) Q4 2024 Earnings Call Summary
Positive
2025-03-10
DarioHealth's earnings call reveals strong financial performance with significant revenue and gross margin growth, alongside successful capital raising. The strategic partnership with AARP and transition to a subscription model are promising. While competitive pressures and regulatory challenges exist, the company's expansion plans and optimistic guidance on GLP-1 program growth are positive indicators. The Q&A section reveals some uncertainty in specific metrics, but overall sentiment remains positive due to the company's strategic initiatives and financial health.
DarioHealth Corp. (DRIO) Q3 2024 Earnings Call Summary
Positive
2024-11-09
The earnings call summary reflects strong financial performance with 111% YoY revenue growth and improved gross margins. The company's strategic shift towards a recurring revenue model and cost management initiatives are positive indicators. The Q&A section highlighted potential growth in B2B2C revenue and stability in B2C revenue. However, challenges in transitioning pharma partnerships and regulatory risks were noted. Overall, the positive financial metrics and strategic initiatives outweigh the risks, suggesting a positive stock price movement over the next two weeks.
DarioHealth Corp. (DRIO) Q2 2024 Earnings Call Summary
Positive
2024-08-10
The earnings call highlights strong revenue growth, high gross margins, and strategic initiatives like AI integration and cost reduction. Despite short-term impacts from a price concession and competitive pressures, the company's long-term growth prospects are promising, with profitability expected by 2025. The Q&A session revealed positive cross-selling efforts and a move towards recurring revenue, reinforcing a positive outlook. Although some management responses lacked clarity, the overall sentiment remains positive due to strategic transformation and growth potential.
People Also Watch
FAQ
What were the key highlights of DRIO’s latest earnings report for FY2025Q3?
How did DRIO’s stock price react after the FY2025Q3 earnings release?
What are the revenue and EPS estimates for DRIO for 2025/Q4?
How does DRIO’s stock price correlate with earnings forecast revisions?
What should investors expect from DRIO’s next earnings report?